South Korean medical aesthetics company Humedix has secured China NMPA approval for its hyaluronic acid filler 'Liporia HARA-L', with a planned Q4 2026 launch in the Chinese market. The development signals a new entrant in China's rapidly growing aesthetic injectables segment, offering overseas distributors and clinic buyers an additional Korean-origin HA filler option.
Regulatory milestone
Humedix announced on June 19 that it obtained medical device item approval from China's National Medical Products Administration (NMPA) for Liporia HARA-L. The filler is manufactured using the same sterile raw materials as those used in injectable and ophthalmic products, ensuring high safety standards. The approval clears the regulatory path for commercial distribution in China.
Market context
According to industry estimates, China's medical aesthetics market reached 370.1 billion yuan (approximately 83 trillion won) last year. The country's large population and growing demand for K-beauty among younger demographics create a favorable environment for Korean aesthetic products. Humedix's entry aligns with this trend, offering a new HA filler option for Chinese clinics.
Distribution and strategy
Humedix has partnered with Shanghai Li Aesthetic (Shangli Esthetics) to handle local distribution in China. CEO Kang Min-jung stated, "We plan to expand our influence in overseas markets." The company aims to leverage its NMPA approval to capture market share in China's competitive filler segment.
What buyers should watch
Overseas distributors and clinic buyers should monitor Humedix's Q4 2026 launch timeline and distribution terms with Shanghai Li Aesthetic. The product's sterile manufacturing process and Korean origin may appeal to clinics seeking high-quality HA fillers. As China's aesthetic market continues to grow, this approval could open opportunities for cross-border supply chain partnerships.
Source: Read the original report | Published: June 19, 2026